7 Or 8 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.7)
-
Publication number: 20150017097Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.Type: ApplicationFiled: October 2, 2014Publication date: January 15, 2015Applicant: BRACCO DIAGNOSTICS INC.Inventors: Edmund C. METCALFE, Jo Anna MONTEFERRANTE, Margaret NEWBORN, Irene KUCHAREWICZ ROPIAK, Ernst SCHRAMM, Gregory W. WHITE, Julius P. ZODDA
-
Patent number: 8933194Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: GrantFiled: May 16, 2012Date of Patent: January 13, 2015Assignee: Palatin Technologies, Inc.Inventors: Wei Yang, Yi-Qun Shi
-
Patent number: 8933031Abstract: Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis.Type: GrantFiled: February 4, 2008Date of Patent: January 13, 2015Assignee: Shanghai First People's HospitalInventors: Hui Zhao, Xun Xu
-
Patent number: 8933035Abstract: A peptide of general formula (I): R1-(AA)nX1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2, and cosmetic and pharmaceutical compositions are disclosed that include at least one peptide of general formula (I), in a physiologically suitable medium. Also disclosed are methods for activating human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation or for cosmetic treatment to treat signs of skin ageing, which include administering a composition containing the peptide of general formula (I) as an active ingredient.Type: GrantFiled: August 31, 2010Date of Patent: January 13, 2015Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20150011483Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use.Type: ApplicationFiled: July 11, 2014Publication date: January 8, 2015Inventors: HOSAHUDYA N. GOPI, IRWIN M. CHAIKEN
-
Publication number: 20150005242Abstract: The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: September 16, 2014Publication date: January 1, 2015Applicants: Institut de Recherches Cliniques de Montreal, Cornell UniversityInventors: Hazel H. SZETO, Peter W. SCHILLER
-
Publication number: 20150004184Abstract: The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides.Type: ApplicationFiled: September 8, 2014Publication date: January 1, 2015Inventors: Thomas MITTS, Felipe JIMENEZ
-
Publication number: 20140378371Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: April 21, 2014Publication date: December 25, 2014Applicant: Symthera Canada Ltd.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20140356285Abstract: Systems and reagents for identification, characterization and/or targeting of particular tissue or cell markers are disclosed. Methods and compositions for in vivo and in vitro targeting of particular targets are also disclosed. Peptides are employed for targeted delivery of therapeutic or imaging agents.Type: ApplicationFiled: September 20, 2012Publication date: December 4, 2014Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini, Mikhail G. Kolonin
-
Publication number: 20140349945Abstract: A PEG-oligopeptide-irinotecan conjugate has the general formula (I) (shown below) and a pharmaceutical composition containing the conjugate are disclosed. In the conjugate, PEG represents polyethylene glycol with a molecular weight of 300-60,000 Daltons; (AA)i represents an oligopeptide, AA represents the same or different amino acids in the oligopeptide; i is an integer of 2-12 representing the number of amino acids in the oligopeptide; j is an integer of 2-12 representing the number of irinotecan connected with the oligopeptide. In the conjugate, each terminal group of PEG can link with multiple irinotecans through oligopeptides, thereby greatly increasing the drug-loading capacity. Modification of the hydrophilic polymer can provide protection for the irinotecan, thereby improving drug absorption, prolonging the action time, enhancing the efficacy, reducing the dose and avoiding the toxic and side-effects.Type: ApplicationFiled: November 7, 2012Publication date: November 27, 2014Applicants: JENKEM TECHNOLOGYCO., LTD.. (TIANJIN), JENKEM TECHNOLOGY CO., LTD(BEIJING)Inventors: Lihua Xu, Wenzhe Huang, Xuan Zhao
-
Patent number: 8889633Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.Type: GrantFiled: March 15, 2013Date of Patent: November 18, 2014Assignee: Mead Johnson Nutrition CompanyInventors: Dirk Hondmann, Eric A. F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140335189Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20140336109Abstract: A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin.Type: ApplicationFiled: December 14, 2012Publication date: November 13, 2014Applicant: Alize Pharma SASInventors: Aart Jan Van Der Lely, Thierry Abribat
-
Patent number: 8883721Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: May 12, 2010Date of Patent: November 11, 2014Assignees: McGill University, The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Patent number: 8883741Abstract: The invention relates to a novel agent having an influence on the genital, sexual and reproductive function of mammals and human beings. More specifically, the invention relates to the use of a heptapeptide of the general formula (I) Thr-Lys-Pro-Arg-Pro-Gly-Pro (SEQ ID NO: 1) as a stimulator of the genital, sexual and reproductive function of mammals and human beings. The invention widens the range of agents available for stimulating the genital, sexual and reproductive function of mammals and human beings.Type: GrantFiled: June 1, 2010Date of Patent: November 11, 2014Assignee: Bio Peptid Company LimitedInventors: Nikolay Fedorovich Myasoedov, Alim Vasilievich Nemersky, Mikhail Alexandrovich Mogutov, Tatiyana Nikolaevna Sollertinskaya, Mstislav Vladilenovich Shoroshov, Dmitry Viktorovich Golikov
-
Publication number: 20140329760Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: ApplicationFiled: October 23, 2013Publication date: November 6, 2014Applicants: Mayo Foundation for Medical Education and Research, Trustees of Dartmouth CollegeInventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Publication number: 20140323415Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly(lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.Type: ApplicationFiled: July 14, 2014Publication date: October 30, 2014Inventors: Holger PETERSEN, Olivier LAMBERT, Rolf LEOFFLER, Michael Ausborn, Jean-Daniel BONNY
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20140322253Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Inventors: Philip Greenberg, Sebastian Ochsenreither
-
Publication number: 20140323393Abstract: A method of treating loss of brain function in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which A is Ala, or absent, B is Ser, Thr or absent, C is Ser, Thr or absent, D is Ser, Thr, Asn, Glu, Arg, Ile, Leu, E is Ser, Thr, Asp, Asn, F is Thr, Ser, Asn, Arg, Gln, Lys, Trp, G is Tyr, and H is Thr, Ser, Arg, Gly. All amino acids in the D peptide are the D stereoisomeric configuration. The peptide composition is administered in a therapeutically effective dose.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Inventor: Michael Ruff
-
Publication number: 20140322336Abstract: Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogenous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and provides protected and sustained release of active agents from the microsphere delivery system. According to the invention, the microspheres preferably are produced by an oil-in-water emulsion method that involves the production of a homogeneous oil phase prepared by mixing active agent and a release-modifying agent, such as arginine, with biodegradable polymer, each dissolved in organic solvent.Type: ApplicationFiled: July 11, 2014Publication date: October 30, 2014Inventors: Byung Ho WOO, Sumeet H. DAGAR, Kang Yong YANG
-
Publication number: 20140314839Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventors: Joseph A. Vetro, Sam D. Sanderson
-
Publication number: 20140315831Abstract: The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.Type: ApplicationFiled: October 25, 2012Publication date: October 23, 2014Inventors: Thomas Kodadek, Yu Gao
-
Publication number: 20140315784Abstract: The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.Type: ApplicationFiled: June 27, 2012Publication date: October 23, 2014Inventors: Mark Bradley, Jeffrey George Andrew Walton, Sunay Vijaykumar Chankeshwara, Mazen Sleiman, George S. Baillie, Lucien Gibson
-
Publication number: 20140314734Abstract: A peptide composition is provi'deo!which specifically inhibits the ability of ? protein kinase C (?PKC) to phosphor/late pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion.Type: ApplicationFiled: August 10, 2012Publication date: October 23, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Nir Qvit, Marie-Helene Disatnik Dziesietnik
-
Patent number: 8865651Abstract: The invention is directed to an anti ageing skin care composition, more in particular a cosmetic anti aging skin care composition. The anti ageing skin care composition of the invention comprise, in a physiologically acceptable medium, (i) at least one peptide from Laminin-1 that is able to promote synthesis of Laminin-5; (ii) at least one peptide capable of at least partially inhibiting neuronal exocytosis; and (iii) at least one tripeptide producing a rapid and strong stimulation of collagen synthesis. The compositions of the present invention are effective in reducing existing wrinkles and/or preventing the formation of new wrinkles.Type: GrantFiled: May 8, 2008Date of Patent: October 21, 2014Assignee: Tupperware Products S.A.Inventors: Stephanus Cornelis Maria Otte, Claudia Amalia Estrada Hernández, Annis Won
-
Patent number: 8859492Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: GrantFiled: May 12, 2012Date of Patent: October 14, 2014Assignee: MetalloPharm, LLCInventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Publication number: 20140296165Abstract: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Blake Paterson, Amir Tamiz, Niranjan Pandey
-
Publication number: 20140294894Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: Alba Therapeutics CorporationInventors: Dorothea Sesardic, Blake Paterson
-
Publication number: 20140296130Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventor: Amir Tamiz
-
Publication number: 20140287002Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventor: Kunwar Shailubhai
-
Publication number: 20140287989Abstract: The present invention relates to compounds which bind to the hydrophobic pocket of the ? clamp, i.e., to the surface of the ? ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target.Type: ApplicationFiled: April 13, 2012Publication date: September 25, 2014Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Dominique Burnouf, Annick Stote, Gilles Guichard, Jerome Wagner, Vincent Olieric
-
Publication number: 20140271553Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Mead Johnson Nutrition (Asia Pacifci) Pte. Ltd.Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140274904Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.Type: ApplicationFiled: May 6, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Xin Qi, Nir Qvit
-
Publication number: 20140271554Abstract: The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140274892Abstract: The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140271586Abstract: The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Mead Johnson Nutrition (Asia Pacific) Pte. Ltd.Inventors: DIRK HONDMANN, ERIC A.F. VAN TOL, GABRIELE GROSS, MARIEKE H. SCHOEMAKER, TEARTSE TIM LAMBERS
-
Patent number: 8835375Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: GrantFiled: August 7, 2007Date of Patent: September 16, 2014Assignee: Applied Nanosystems B.V.Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Patent number: 8835377Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.Type: GrantFiled: August 26, 2011Date of Patent: September 16, 2014Assignee: UGP Therapeutics, Inc.Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Publication number: 20140256625Abstract: The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis.Type: ApplicationFiled: July 9, 2012Publication date: September 11, 2014Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Charlotte Hauser, Anupama Lakshmanan
-
Publication number: 20140256613Abstract: Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: September 11, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Shanjana Awasthi
-
Patent number: 8828940Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: GrantFiled: December 14, 2010Date of Patent: September 9, 2014Assignee: Compugen Ltd.Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8829159Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.Type: GrantFiled: April 14, 2009Date of Patent: September 9, 2014Assignee: The General Hospital CorporationInventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
-
Patent number: 8822442Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.Type: GrantFiled: October 28, 2005Date of Patent: September 2, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
-
Publication number: 20140235544Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Yitzchak Hillman
-
Publication number: 20140235557Abstract: The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents.Type: ApplicationFiled: June 20, 2012Publication date: August 21, 2014Applicants: Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Universite Joseph Fourier, Institut National De La Sante Et De La Recherche Medicale (INSERM)Inventor: Michel De Waard
-
Patent number: 8809276Abstract: New peptides activating extracellular matrix protein synthesis in the skin, a cosmetic composition that includes such peptides as an active agent, and cosmetic care methods intended to delay or treat cutaneous signs of aging and photoaging by applying such peptides and/or cosmetic compositions are described.Type: GrantFiled: February 17, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8809275Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignees: The Board of Trustees of the University of Arkansas, University of South CarolinaInventors: Shannon Servoss, Melissa Moss
-
Patent number: 8809279Abstract: Peptide compounds of the following general formula (I): R1-(AA)n-X1-X2-X3-Lys-Lys-Gln-Lys-Trp-X4-(AA)p-R2 are disclosed herein. The peptide compounds can be used as Telomeric repeat-binding factor 2 (TRF2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (DNA) double-strand breaks. In addition, cosmetic compositions that include at least one peptide of general formula (I) in a physiologically acceptable medium are disclosed along with methods for preventing and/or treating cutaneous signs of aging and photoaging.Type: GrantFiled: April 27, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140227238Abstract: The present invention concerns peptides having protective effect towards inflammatory activity of a-gliadin 31-43 peptide in celiac disease and therefore can be used for preventive and therapeutic purpose by administration thereof to subjects at high risk to develop celiac disease and/or celiac subjects just before a gluten containing meal to be ingested.Type: ApplicationFiled: September 18, 2012Publication date: August 14, 2014Applicants: Istituto Superiore Di Sanita, CRA-Sonsiglio per La Ricerca E LAInventors: Marco Silano, Luigi Cattivelli, Pasquale De Vita, Luigi Maiuri, Donatella Bianca Maria Ficco